



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kirchholtes et al.

Serial No.: 09/787,215

Filed: May 17, 2001

For: HIGH PURITY COMPOSITION
COMPRISING (7 ALPHA, 17 ALPHA)-17-
HYDROXY-7-METHYL-19-NOR-17-
PREGN-5(10)-EN-20-YN-3-ONE

Confirmation No.: 7592

Examiner: S. Jiang

Group Art Unit: 1617

Attorney Docket No.: 1963-5047US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL994825879US

Date of Deposit with USPS: February 9, 2005

Person making Deposit: Allen C. Turner

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

Other Documents

Closed Record in the Petition of Arrow Generics Limited for Revocation of Claims in European Patent EP 1 121 375 B1 (June 9, 2004). Received from counsel on July 7, 2004.

Communication from Akzo Nobel with European Patent Office in response to Oppositions to EP 1 121 375 B1 (October 15, 2004).

Letter from Cavellier regarding Opposition against Columbian Patent Application 99065751 filed 15 October 1999 (June 2, 2004).

SCHOUTEN et al., Structure of the Triclinic Modification of 17beta-Hydroxy-19-nor-7 alpha-methyl-17alpha-pregn-5(10)-en-20-yn-3-one (ORG OD14), pp. 1754-56, International Union of Crystallography (1991).

Expert Report of Dr. Roger Newton in the Petition of Arrow Generics Limited for Revocation of Claims in European Patent EP 1 121 375 B1 (October 16, 2004).

V. Alexéev, Análise Quantitativa, pages 97-98 (Livraria Lopes da Silva, ed. Porto, pp. 97-98, 1983).

Levine et al. Hungarian Patent 160797 (January 12, 1971).

WATERS, An Introduction to Practical Organic Chemistry, pages 1-35 (London, UK 1934).

DEFENCES and COUNTERCLAIM, In the Court of Session, Intellectual Property Cause, Organon Labs, Ltd et al. v. Norton Healthcare. Received from counsel on January 10, 2005.

Presentation of Laboratorios Recalcine S.A. against Chilean Patent Application 2343-1999 (July 28, 2003). (English language translation).


Opposition by Gynopharm S.A. against Columbian Patent Application file number 99065751 (December 2, 2002). (English language translation).

Opposition by Asociacion de Laboratorios Farmaceuticos (ALAFAR) against application for Ecuadorian patent No. SP-99-3181 (June 2, 2000). (English language translation).

Serial No.: 09/787,215

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits subsequent to the filing of an RCE in the above-identified application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a stylized flourish extending to the right.

Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922


Date: February 9, 2005

ACT/bv

Enclosures: Form PTO/SB/08

Copy of documents cited

Document in ProLaw



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449, PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/787,215
Filing Date	May 17, 2001
First Named Inventor	Kirchholtes et al.
Group Art Unit	1617
Examiner Name	S. Jiang
Attorney Docket Number	1963-50471JS

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Closed Record in the Petition of Arrow Generics Limited for Revocation of Claims in European Patent EP 1 121 375 B1. (May 11, 2004)	
		Communication of proprietor Akzo Nobel with European Patent Office regarding Oppositions to EP 1 121 375 B1 (October 15, 2004).	
		Letter from Cavalier regarding Opposition against Columbian Patent Application 99065751 filed 15 October 1999 (June 2, 2004).	
		SCHOUTEN et al., Structure of the Triclinic Modification of 17beta-Hydroxy-19-nor-7 alpha-methyl-17alpha-pregn-5(10)-en-20-yn-3-one (ORG OD14), 1991, pp. 1754-56, International Union of Crystallography (1991).	
		Expert Report of Dr. Roger Newton in the Petition of Arrow Generics Limited for Revocation of Claims in European Patent EP 1 121 375 B1 (October 16, 2004).	
		V. Alexéev, <i>Análise Quantitativa</i> , pages 97-98 (Livraria Lopes da Silva, eds. Portugal).	X
		Levine et al. Hungarian Patent Application 160797 (October 30, 1973).	
		WATERS, <i>An Introduction to Practical Organic Chemistry</i> , pages 1-35 (London, UK 1934).	
		DEFENCES and COUNTERCLAIM, In the Court of Session, Intellectual Property Cause, Organon Labs, Ltd et al. v. Norton Healthcare (United Kingdom, 2004).	
		Presentation of Laboratorios Recalcine S.A. against Chilean Patent Application 2343-1999 (July 29, 2003). (English language translation).	
		Opposition by Gynopharm S.A. against Columbian Patent Application file number 99065751 (Columbia, December 2, 2002). (English language translation).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number 09/787,215

Filing Date May 17, 2001

First Named Inventor Kirchholtes et al.

Group Art Unit 1617

Examiner Name S. Jiang

Attorney Docket Number 1963-50471US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Opposition against application for Ecuadorian patent No. SP-99-3181 (Ecuador 2000).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.